Citi analyst Patrick Donnelly downgraded Bio-Rad (BIO) to Neutral from Buy with a price target of $300, down from $375. The firm does not see a recovery path for the company’s process chromatography business, which it views as Bio-Rad’s growth and margin growth engine. Further, the company faces uncertainties in the China diagnostics space, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO: